Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.

CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.

Search Results

1277 Results

1191 – HIV Serologic Reactivity in Persons With HIV Who Started ART During Acute/Early Stages of Infection

Background Persons with HIV (PWH) who receive antiretroviral treatment (ART) beginning in acute/early stages of infection may fail to develop antibody reactivity or revert to nonreactive levels on serological assays. Seroreactivity after prolonged viral suppression in PWH treated in acute/early stages of infection has not been previously characterized. Methods RV254 cohort study identified PWH with…

1198 – Impact of Point-of-Care HIV-1 RNA Testing on Time to HIV Confirmation and ART Start in Buenos Aires

Background In Argentina, HIV diagnosis is confirmed through RNA-HIV (VL), usually performed in specialized referral laboratories. People need a second appointment to receive HIV confirmation (HIV-C), which is required to initiate antiretroviral therapy (ART). Time to HIV-C depends on laboratory and administrative factors. Shortening the diagnostic process is the first step towards implementing test and…

1185 – Validation of a National HIV Testing Eligibility Screening Tool in Tanzania

Background In 2020, Tanzania introduced a 16-question screening tool to determine adult eligibility for HIV testing services (HTS). This validation study compares the characteristics of the current tool to a) an optimized tool and b) HIV self-testing (HIVST).  Methods From March to June 2024, adults aged ≥15 years with unknown HIV status seeking care were…

1164 – Projecting Demographics and Causes of Death Among People With HIV in Western Europe to 2050

Background Antiretroviral therapy (ART) scale-up in Western Europe has reduced the incidence of AIDS, increased life expectancies, and led to an aging population of people with HIV (PWH). We aimed to predict cause-specific mortality patterns in Western Europe in the context of changes in demographics and ART use. Methods A deterministic, compartmental model was parameterised…

1147 – Missed Opportunities for Drug Use Screening and Discussions Among People With HIV

Background Drug use is more prevalent among people with HIV and can worsen HIV-related outcomes. Screening and discussions about drug use with a healthcare provider (HCP) have been found to be associated with higher perceived need and receipt of drug treatment. We explored differences in past-year drug use, screening, and discussion with a HCP among…

1110 – Time to Antiretroviral Initiation Among Transgender Women Living With HIV in France (1997-2022)

Background Despite a global HIV prevalence of nearly 20% among transgender women (TW), some studies have shown that this population often experiences longer time intervals within the continuum of care. This study aims to describe the evolution of these time intervals and analyze the impact of sociodemographic and clinical factors on the time to antiretroviral…

1131 – Addressing Advanced HIV Disease: Insights on CD4 Testing and AHD Prevalence at PEPFAR Sites

Background Advanced HIV Disease (AHD) in individuals aged 5 and older is defined by a CD4 count below 200 cells/mm³ or World Health Organization (WHO) stage 3 or 4 conditions. Despite the global shift to a test-and-treat approach for people living with HIV, many in low- and middle-income countries still present with AHD at diagnosis,…

1153 – Introduction and Acquisition of HIV-1 Related to Recent Migration to Quebec (2016-2023)

Background There has been a marked rise in new diagnoses in Montreal from 140 cases in 2021 to 310 in 2022. Population-level viral phylogenetics can provide a unique molecular framework to better ascertain the impact of migration on the introduction and crossover of subtype B and non-B subtype epidemics among Men having Sex with Men…

1078 – Durable Viral Suppression Using Different Definitions in a Ryan White HIV Program Clinic, 2018-2021

Background Durable viral suppression (DVS), a metric that evaluates viral suppression (VS) over time, has many different definitions. The Centers of Disease Control and Prevention and the Ryan White HIV/AIDS Program (RWHAP) define VS for a year as the last viral load (VL) in the year is suppressed and require a person with HIV (PWH)…

1162 – Reducing HIV Diagnoses and Mortality Rate Further Increases Aging Resource Needs for PWH Into 2040

Background Increased survival has changed the age distribution of people with HIV in the United States (U.S.). Over 2010-2022, the fraction of people with diagnosed HIV (PWDH) aged > 50 years increased to 54%. Forecasts of future age distributions are needed to inform resource planning. Methods We used a life table model with age-specific mortality to predict future…